These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 1749373)
41. Answers to questions about the acellular pertussis vaccine. Kimmel SR Am Fam Physician; 1993 Jun; 47(8):1825-32. PubMed ID: 8498289 [TBL] [Abstract][Full Text] [Related]
42. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(39):1078-9. PubMed ID: 18830212 [TBL] [Abstract][Full Text] [Related]
43. Adverse reactions of a pertussis toxoid vaccine in a double-blind placebo-controlled trial. Taranger J; Trollfors B; Knutsson N Dev Biol Stand; 1997; 89():109-12. PubMed ID: 9272340 [TBL] [Abstract][Full Text] [Related]
44. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules. Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838 [TBL] [Abstract][Full Text] [Related]
52. Diphtheria and tetanus toxoids and pertussis vaccine litigation. Lokietz H Am J Dis Child; 1991 Apr; 145(4):425. PubMed ID: 2012023 [No Abstract] [Full Text] [Related]
53. SIDS and immunization. Beal SM Med J Aust; 1990 Jul; 153(2):117. PubMed ID: 2366695 [No Abstract] [Full Text] [Related]
54. Estimating vaccine costs for EPI (Expanded Programme on Immunization) cost-effectiveness analysis. Feilden R Int J Health Plann Manage; 1990; 5(3):221-6. PubMed ID: 10113383 [No Abstract] [Full Text] [Related]
55. The immunization controversy. A lesson from the Renaissance. Mann FD Postgrad Med; 1986 Nov; 80(6):255-6. PubMed ID: 3774663 [No Abstract] [Full Text] [Related]
56. A change in vaccine efficacy and duration of protection explains recent rises in pertussis incidence in the United States. Gambhir M; Clark TA; Cauchemez S; Tartof SY; Swerdlow DL; Ferguson NM PLoS Comput Biol; 2015 Apr; 11(4):e1004138. PubMed ID: 25906150 [TBL] [Abstract][Full Text] [Related]
57. Combination vaccines against diarrheal diseases. Venkatesan MM; Van de Verg LL Hum Vaccin Immunother; 2015; 11(6):1434-48. PubMed ID: 25891647 [TBL] [Abstract][Full Text] [Related]
58. Food and Drug Administration approval of use of diphtheria and tetanus toxoids and acellular pertussis vaccine. Centers for Disease Control (CDC) MMWR Morb Mortal Wkly Rep; 1991 Dec; 40(50):881-2. PubMed ID: 1749373 [No Abstract] [Full Text] [Related]
59. FDA approval of a fourth acellular pertussis vaccine for use among infants and young children. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 1998 Nov; 47(43):934-6. PubMed ID: 9822368 [TBL] [Abstract][Full Text] [Related]
60. Food and Drug Administration approval of an acellular pertussis vaccine for the initial four doses of the diphtheria, tetanus, and pertussis vaccination series. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 1996 Aug; 45(31):676-7. PubMed ID: 8778580 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]